Dorsey Wright & Associates Vertex Pharmaceuticals Inc Transaction History

Dorsey Wright & Associates

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$285.76 - $321.48 $113,732 - $127,949	-398 Reduced 6.74%	5,504 $1.59 Million
Q2 2022 Jul 20, 2022	BUY	$234.96 - $292.55 $1.39 Million - $1.73 Million	5,902 New	5,902 $1.66 Million
Q4 2020 Jan 28, 2021	SELL	$207.01 - $276.09 $2.56 Million - $3.41 Million	-12,354 Closed	0 $0
Q3 2020 Oct 28, 2020	SELL	$255.65 - $303.1 $221,904 - $263,090	-868 Reduced 6.56%	12,354 $3.36 Million
Q2 2020 Jul 23, 2020	SELL	$225.48 - $295.8 $132,131 - $173,338	-586 Reduced 4.24%	13,222 $3.84 Million
Q1 2020 Apr 20, 2020	BUY	$199.77 - $247.81 $2.76 Million - $3.42 Million	13,808 New	13,808 $3.29 Million
Q2 2019 Jul 02, 2019	SELL	$164.61 - $190.37 $2.72 Million - $3.14 Million	-16,505 Closed	0 $0
Q1 2019 Apr 04, 2019	BUY	$163.73 - $194.7 $2.7 Million - $3.21 Million	16,505 New	16,505 $3.04 Million
Q4 2018 Jan 07, 2019	SELL	$151.91 - $192.21 $2.6 Million - $3.28 Million	-17,087 Closed	0 $0
Q3 2018 Oct 12, 2018	BUY	$167.73 - $192.74 $96,780 - $111,210	577 Added 3.49%	17,087 $3.29 Million
Q2 2018 Jul 06, 2018	BUY	$145.72 - $169.96 $201,385 - $234,884	1,382 Added 9.14%	16,510 $2.81 Million
Q1 2018 Apr 30, 2018	BUY	$151.6 - $177.13 $52,908 - $61,818	349 Added 2.36%	15,128 $2.47 Million
Q4 2017 Feb 14, 2018	SELL	$137.28 - $155.55 $1.19 Million - $1.35 Million	-8,651 Reduced 36.92%	14,779 $2.22 Million
Q3 2017 Nov 06, 2017	BUY	$148.13 - $162.24 $1.6 Million - $1.76 Million	10,830 Added 85.95%	23,430 $3.56 Million
Q2 2017 Aug 10, 2017	BUY	N/A	12,600	12,600 $1.62 Million

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Dorsey Wright & Associates, based on Form 13F filings with the SEC.

Stay updated on Dorsey Wright & Associates with notifications on news.